Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Friendly Fire? Tavenner Nomination Held Up By Sen. Harkin

This article was originally published in The Gray Sheet

Executive Summary

While the Senate Finance Committee April 23 agreed to endorse Marilyn Tavenner to head CMS, Sen. Tom Harkin, D-Iowa, Chairman of the Senate HELP Committee, put a block on her full Senate approval the next day.

You may also be interested in...



NIH, BRAIN Research Gets Boost In 2014 Senate Labor/HHS Bill

An appropriations bill passed by a Senate committee would increase the National Institutes of Health’s funding by $307 million to $31 billion in fiscal year 2014, including $40 million for President Obama’s BRAIN neurotechnology research initiative. Senate Appropriations Committee Chair Barbara Mikulski says she is determined to bring the Labor/HHS funding bill to the floor for debate.

News In Brief

Tavenner confirmed as CMS chief. DePuy phases out metal hips. More news

Tavenner’s Confirmation For CMS One Step Closer As Harkin Lifts Hold

Sen. Harkin said he is lifting his hold on a Senate vote on Marilyn Tavenner’s nomination to head CMS because he recognizes the agency needs a permanent leader as it faces the challenges of implementing the Affordable Care Act’s coverage expansion provisions.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel